Payment overview · 2025
General Payments
$13,274.45
105 reported records · 23 companies
Healthcare provider profile · identity verified
Henry C Yee, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ALHAMBRA, CA · NPI 1285724724
Verified facts
What the public records show
CMS Open Payments records show Henry C Yee, MD received $13,274.45 in general payments during 2025 across 105 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 48.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adempas, Creon, Farxiga, Jardiance, Kerendia, Linzess, Lokelma, Nexletol, Ozempic, Rybelsus, Trelegy Ellipta, Verquvo, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 404 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 1243 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Adempas by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 603 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 785 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Linzess by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Adempas by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 450 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $6,392.54 | 48.2% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $4,639.11 | 35.0% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $326.44 | 2.5% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $223.67 | 1.7% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$212.89 | 1.6% | 6 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $192.14 | 1.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $182.35 | 1.4% | 5 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $157.32 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $150.53 | 1.1% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.05 | 1.1% | 6 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $144.75 | 1.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $83.68 | 0.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $70.84 | 0.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $69.67 | 0.5% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $65.79 | 0.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.33 | 0.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $35.06 | 0.3% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.59 | 0.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.39 | 0.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.30 | 0.2% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $19.64 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.06 | 0.1% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $14.31 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,008.00 | 2 |
| Food and Beverage | $3,505.17 | 97 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,200.00 | 1 |
| Travel and Lodging | $542.43 | 4 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $6,384.30 | 21 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $4,185.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $284.31 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $264.07 | 4 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $192.14 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $173.32 | 9 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $157.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $150.53 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $148.05 | 6 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $144.75 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $142.29 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $135.23 | 6 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $130.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $122.06 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $83.68 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $70.84 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $69.67 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $65.79 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $58.63 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.33 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $40.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| TYRX Normalized: tyrx |
Device | Medtronic, Inc. | $27.95 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $20.75 | 2 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.64 | 2 | 2025 |
Source payment records
|
|||||
| MyoSPECT Normalized: myospect |
Device | GE HEALTHCARE | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $10.77 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $4.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adempas adempas |
2025 | Adempas | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 150 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 1243 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 603 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 293 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 277 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 61 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 170 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 152 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 84 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
150 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
277 | 80 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
404 | 67 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
1243 | 292 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
293 | 66 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
603 | 122 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
785 | 147 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
322 | 79 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
152 | 41 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
277 | 80 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
450 | 91 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
170 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2488 | 579 |
| Ezetimibe | Ezetimibe | 2250 | 529 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2045 | 464 |
| Ranolazine Er | Ranolazine | 1616 | 351 |
| Metoprolol Succinate | Metoprolol Succinate | 1350 | 305 |
| Clopidogrel | Clopidogrel Bisulfate | 1327 | 302 |
| Farxiga | Dapagliflozin Propanediol | 1243 | 292 |
| Losartan Potassium | Losartan Potassium | 1027 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 1008 | 239 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 877 | 171 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 873 | 178 |
| Vascepa | Icosapent Ethyl | 827 | 156 |
| Eliquis | Apixaban | 785 | 147 |
| Fenofibrate | Fenofibrate Nanocrystallized | 729 | 153 |
| Xarelto | Rivaroxaban | 672 | 128 |
| Amiodarone Hcl | Amiodarone Hcl | 641 | 137 |
| Jardiance | Empagliflozin | 603 | 122 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 589 | 156 |
| Nebivolol Hcl | Nebivolol Hcl | 559 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 469 | 99 |
| Entresto | Sacubitril/Valsartan | 450 | 91 |
| Brilinta | Ticagrelor | 404 | 67 |
| Terazosin Hcl | Terazosin Hcl | 402 | 93 |
| Digoxin | Digoxin | 401 | 85 |
| Gabapentin | Gabapentin | 384 | 107 |
| Repatha Sureclick | Evolocumab | 383 | 74 |
| Furosemide | Furosemide | 376 | 117 |
| Icosapent Ethyl | Icosapent Ethyl | 371 | 129 |
| Inpefa | Sotagliflozin | 369 | 70 |
| Montelukast Sodium | Montelukast Sodium | 358 | 77 |
| Hydralazine Hcl | Hydralazine Hcl | 326 | 85 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 322 | 79 |
| Carvedilol | Carvedilol | 316 | 68 |
| Kerendia | Finerenone | 293 | 66 |
| Sotalol | Sotalol Hcl | 288 | 69 |
| Linzess | Linaclotide | 277 | 80 |
| Nitroglycerin | Nitroglycerin | 264 | 196 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 257 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 62 |
| Dapagliflozin | Dapagliflozin Propanediol | 233 | 106 |
| Tradjenta | Linagliptin | 228 | 42 |
| Metformin Hcl | Metformin Hcl | 208 | 49 |
| Potassium Chloride | Potassium Chloride | 204 | 58 |
| Valsartan | Valsartan | 186 | 48 |
| Cilostazol | Cilostazol | 173 | 29 |
| Rybelsus | Semaglutide | 170 | 33 |
| Mexiletine Hcl | Mexiletine Hcl | 168 | 45 |
| Meclizine Hcl | Meclizine Hcl | 160 | 77 |
| Famotidine | Famotidine | 152 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 152 | 41 |
| Creon | Lipase/Protease/Amylase | 150 | 42 |
| Febuxostat | Febuxostat | 150 | 31 |
| Januvia | Sitagliptin Phosphate | 148 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 147 | 35 |
| Meloxicam | Meloxicam | 146 | 60 |
| Spironolactone | Spironolactone | 138 | 38 |
| Alendronate Sodium | Alendronate Sodium | 119 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 116 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 33 |
| Fenofibrate | Fenofibrate | 105 | 20 |
| Ozempic | Semaglutide | 105 | 20 |
| Donepezil Hcl | Donepezil Hcl | 102 | 22 |
| Labetalol Hcl | Labetalol Hcl | 102 | 24 |
| Lidocaine | Lidocaine | 102 | 26 |
| Praluent Pen | Alirocumab | 101 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 96 | 36 |
| Nifedipine Er | Nifedipine | 95 | 18 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 92 | 23 |
| Omeprazole | Omeprazole | 91 | 25 |
| Corlanor | Ivabradine Hcl | 89 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 88 | 30 |
| Celecoxib | Celecoxib | 86 | 34 |
| Multaq | Dronedarone Hcl | 85 | 16 |
| Nateglinide | Nateglinide | 84 | 16 |
| Verquvo | Vericiguat | 84 | 15 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 83 | 23 |
| Lisinopril | Lisinopril | 83 | 19 |
| Fenofibrate | Fenofibrate,micronized | 73 | 17 |
| Finasteride | Finasteride | 71 | 19 |
| Nexletol | Bempedoic Acid | 71 | suppressed |
| Memantine Hcl | Memantine Hcl | 62 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 61 | 20 |
| Pregabalin | Pregabalin | 60 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 57 | 15 |
| Hydrocortisone | Hydrocortisone | 56 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | 11 |
| Azithromycin | Azithromycin | 51 | 45 |
| Midodrine Hcl | Midodrine Hcl | 51 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 14 |
| Glipizide | Glipizide | 48 | suppressed |
| Atenolol | Atenolol | 45 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 20 |
| Glimepiride | Glimepiride | 41 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 40 | suppressed |
| Telmisartan | Telmisartan | 39 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 38 | 22 |
| Latanoprost | Latanoprost | 38 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 38 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 37 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 37 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | 16 |
| Azelastine Hcl | Azelastine Hcl | 35 | 11 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Memantine Hcl Er | Memantine Hcl | 32 | 11 |
| Repaglinide | Repaglinide | 32 | suppressed |
| Ursodiol | Ursodiol | 32 | suppressed |
| Opsumit | Macitentan | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Adempas | Riociguat | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 17 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 29 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Humulin R | Insulin Regular, Human | 28 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Cyclosporine | Cyclosporine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 13 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Crestor | Rosuvastatin Calcium | 16 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Acetylcysteine | Acetylcysteine | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Theophylline | Theophylline Anhydrous | 14 | suppressed |
| Effient | Prasugrel Hcl | 13 | suppressed |
| Exemestane | Exemestane | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,274.45 · 105 records | Bayer Healthcare Pharmaceuticals Inc. | ACCOLADE SR, AREXVY, ATRICLIP LAA EXCLUSION SYSTEM, AURORA EV-ICD MRI SURESCAN, Adempas, BREZTRI, BodyGuardian, CAMZYOS, CAPVAXIVE, CREON, EMBLEM MRI S-ICD, EVENITY, FARXIGA, GALLANT, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, LOKELMA, LUX-Dx Insertable Cardiac Monitor, MICRA, MYCARELINK, MyoSPECT, NEXLETOL, Ozempic, PANCREAZE, REPATHA, REZDIFFRA, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, TRELEGY ELLIPTA, TYRX, VERQUVO, Varithena Administration Pack, YUPELRI, ZENPEP | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adempas play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error